MOUNTAIN VIEW, Calif., Sept. 12 IRIDEXCorporation (Nasdaq: IRIX) announced today the appointment of William M. Mooreto its Board of Directors. Mr. Moore, a director at BlueLine Partners,replaces Robert K. Anderson who has left the Board of Directors for personalreasons. IRIDEX recently completed a private placement of equity withBlueLine and as part of the financing BlueLine has the right to designate anindividual for appointment to the IRIDEX Board of Directors.
"Will is a great addition to our Board as he brings 25 years of experienceleading medical device businesses," said Theodore A. Boutacoff, Chairman ofthe Board at IRIDEX. "Will's financial, marketing and overall managementexpertise will be key assets to IRIDEX as we continue to grow the Company. Weare delighted with Will's appointment and look forward to working with him onour shared goal of enhancing shareholder value. At the same time, on behalfof the entire Board, I would like to thank Bob Anderson for his eight years ofservice as an IRIDEX Director. We will miss his wisdom, wit andcontributions."
Will Moore currently serves on the Board of Directors of Criticare Systemsand Natus Medical Inc. (Nasdaq: BABY) a company he co-founded in 1990 and forwhich he served as its CEO until 1993. Mr. Moore was aco-founder and, from 1998 until 2003, CEO of MetaSENSORS Inc. a health caredevelopment company. From 1993 to 1995, Mr. Moore was the Vice President ofMarketing and Sales and a member of the Board of Directors of Arzco MedicalSystems Inc. He negotiated the acquisition of the company from the MarmonGroup and later the sale of the assets to Baxter Healthcare Inc. In addition,from 1993 to 1998, Mr. Moore served on the Board of Directors of ResponsiveMedical Applications Inc. and negotiated the sale of the company to HillRomInc. From 1983 to 1988, Mr. Moore was the Director of Marketing for NellcorInc., now a division of TYCO Inc. during which time sales grew from zero toover $100 million. Mr. Moore earned his B.S. degree from the University ofUtah.
"I am excited about joining the Board of Directors at IRIDEX," said Mr.Moore. "IRIDEX has earned a reputation of developing laser products that areclinically effective, reliable, portable, versatile and affordable, and itsacquisition of the Laserscope aesthetic business has helped diversify theCompany's portfolio. With BlueLine's recent infusion of capital, I believethe Company is well on its way to recovering from the challenges of theLaserscope transaction. IRIDEX is continuing to implement other cost-savingstrategies to realize synergies between the ophthalmology and new aestheticsbusinesses, and I am confident that the results of our efforts will help bringa return to profitability."
IRIDEX Corporation is a leading worldwide provider of therapeutic basedlaser systems, disposable laser probes and delivery devices to treat eyediseases in ophthalmology and skin disorders in the aesthetics market. IRIDEXproducts are sold in the United States through a direct sales force andinternationally through a combination of a direct sales force and a network ofapproximately 97 independent distributors into 107 countries. For furtherinformation, visit the Company's website at http://www.iridex.com.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaningof Section 27A of the Securities Act of 1933, as amended and Section 21E ofthe Securities Act of 1934, as amended, relating to the company's use of theproceeds of the financing, growth in the company's revenues, the company'sfuture growth, its ability to successfully integrate the aesthetics businessacquired from Laserscope and to realize projected synergies between theophthalmology and new aesthetics businesses, and its ability to return toprofitability. Actual results could differ materially and adversely from